(NASDAQ: CDTX) Cidara Therapeutics's forecast annual revenue growth rate of 45.05% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.49%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.69%.
Cidara Therapeutics's revenue in 2024 is $46,378,000.On average, 1 Wall Street analysts forecast CDTX's revenue for 2024 to be $127,317,270, with the lowest CDTX revenue forecast at $127,317,270, and the highest CDTX revenue forecast at $127,317,270. On average, 1 Wall Street analysts forecast CDTX's revenue for 2025 to be $488,878,246, with the lowest CDTX revenue forecast at $488,878,246, and the highest CDTX revenue forecast at $488,878,246.
In 2026, CDTX is forecast to generate $604,608,778 in revenue, with the lowest revenue forecast at $604,608,778 and the highest revenue forecast at $604,608,778.